|
I always wondered why no single major medical database seemed to be organized too, RB. I had thought that was part of the purpose of the cancer registry but probably that was organized more for bean counting than to help with figuring out all the differences to find solutions. And since testing for HER2 wasn't "standard" until there was greater recognition that traztuzumab would make a difference, there was only the limited coordination of whatever info happened to be collected in those clinical trials that were specific to HER2's.
In regard to the original comments the onc made, the choices for early stage aren't at all clear. The same oncs that advised me to do "everything" (chemo, rads, hormonal treatment) now advise me not to do "everything" and not to do traztuzumab late. Then there is the open question, if you find an onc who will authorize it (considering that we may only get it for a limited time unless we have a recurrence), would it be better to wait until the dust settles and they understand which of us do actually benefit from it?
And for those who don't benefit, could having the unnecessary traztuzumab effect any changes that make their cancers harder to treat down the road with anything else effectively?
A.A.
|